Cover Story
Free
By Matthew Bin Han Ong
FDA's passive reliance on self-reporting by hospitals and device manufacturers allowed harm caused by power morcellators to go unnoticed for over two decades—likely contributing to injury and deaths of hundreds of women, according to the U.S. Government Accountability Office said.
In Brief
Funding Opportunities
Drugs & Targets
Trending Stories
- Beyond the $500B Stargate Project: The frontier of AI in oncology beckons
- What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - Trump 2016: A look back at the 45th president’s impact on oncology
- FDA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers
- Felix Feng, GU cancer researcher who made fundamental discoveries in genomics, dies at 48
- Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills